Rationale Behind Survivin Inhibition as a Potential Therapeutic Strategy in Head and Neck Carcinoma too Gino Marioni Letter to the Editor 29 August 2012 Pages: 1 - 2
In Reply: Response to Marioni David N. ChurchDenis C. Talbot Letter to the Editor 30 August 2012 Pages: 3 - 3
Emerging Concerns When Evidence-Based Medicine Is Translated into Real Life: The Case of Neoadjuvant Chemotherapy in Ovarian Cancer Antonio González-MartínLuis Chiva Invited Commentary 09 October 2012 Pages: 4 - 6
Risk Stratification in Ductal Carcinoma in Situ: The Role of Genomic Testing Gary M. Freedman Breast Cancer (KR Fox, Section Editor) 23 November 2012 Pages: 7 - 13
The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced Breast Cancer Michael Gnant Breast Cancer (KR Fox, Section Editor) 28 September 2012 Pages: 14 - 23
On the Pathway to Success: Defining Subtypes of Gliomas for Better Treatment Selection and Refining the Meaning of Success Mark R. Gilbert Neuro-oncology (MR Gilbert, Section Editor) 23 November 2012 Pages: 24 - 26
Measuring Clinical Benefit: Use of Patient-Reported Outcomes (PRO) in Primary Brain Tumor Clinical Trials Terri S. Armstrong Neuro-oncology (MR Gilbert, Section Editor) 03 October 2012 Pages: 27 - 32
Tumor Prognostic Factors and the Challenge of Developing Predictive Factors Emma B. HollidayErik P. Sulman Neuro-oncology (MR Gilbert, Section Editor) 07 December 2012 Pages: 33 - 46
Success at Last: A Molecular Factor That Informs Treatment Andrew B. Lassman Neuro-oncology (MR Gilbert, Section Editor) 18 December 2012 Pages: 47 - 55
Incorporation of Prognostic and Predictive Factors Into Glioma Clinical Trials Derek R. JohnsonEvanthia Galanis Neuro-oncology (MR Gilbert, Section Editor) 06 November 2012 Pages: 56 - 63